News

Piramal Pharma Ltd share price gained 1.69% to Rs 198.45 after the company`s net profit witnessed a sharp fall of 107.25% to Rs 5.03 crore, while revenue from operations increased 15.29% to Rs 2617.06 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, easing 4.06%. It has improved by 3.17% over last one week and eased lower by 0.26% in last one month while the market capitalization of Piramal Pharma Ltd has marginally improved by 3.85% and 0.81% in the same period respectively. Profit before tax (PBT) of Piramal Pharma Ltd stood at Rs 81.63 crore in Q3 FY26, tanking 276.76% year-on-year, and nosediving by 1194.24% quarter-on-quarter. EBITDA came in at Rs 313 crore, surging by 236.03% YoY and jumping 195.69% sequentially. Total expenses posted a minor rise of 8.84% to Rs 2501.47 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 645.82 crore, contracting by 10.89% YoY, while employee benefits expense was at Rs 714.32 crore, inching up 5.73% YoY. For the TTM ended FY26, revenue from operations eased 3.08% to Rs 8869.08 crore, while net profit tumbled by 457.66% to Rs 325.94 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 132392% to Rs 708.32 crore, and PBT collapsed by 142.46% to Rs 176.06 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 1652.6 crore in FY26, as against Rs 892.3 crore in FY25. Piramal Pharma Ltd slipped 2.34% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.19% during the same period.

Piramal Pharma Limited will hold a board meeting on Tuesday, 27th October 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th September 2026, according to a regulatory filing. The trading window for the company`s securities will remain closed from Thursday, 1st October 2026, until Thursday, 29th October 2026.

Piramal Pharma Limited announced that Jeffrey Hampton will retire as President and COO of Piramal Critical Care, effective November 27, 2026, and that Brian Guy has been appointed as President and COO of Piramal Critical Care, effective October 19, 2026.

Piramal Pharma Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in securities of the company will be closed for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the half year ending September 30, 2026, with the date of the board meeting to approve the results to be communicated later.

Piramal Pharma Limited has completed the acquisition of 1,46,400 equity shares of Rs 10 each from existing shareholders of Yapan Bio Private Limited for approximately Rs 76 crores, increasing its stake in the contract development and manufacturing organization from 33.33% to 74.00%, thereby making Yapan a subsidiary of Piramal Pharma.